Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

SCI Annual Report 2017

Jul 12, 2017

52383_rns_2017-07-12_e0bd9158-3241-4315-84c7-dc3086087e62.pdf

Annual Report

Open in viewer

Opens in your device viewer

員工數Employee:242 設立日期:中華民國七十六年九月十八日 Date of establishment: Sep. 18, 1987 資本額Capital:新台幣795佰萬元(NTD 795mn) 營業項目Business: 原料藥API(58.41%) 中間體Intermediate(30.61%) 特用化學品 Custom-made chemicals(10.98%)

公司概況Outline

Y2016 2017.Q2

洲Europe
34.40% 45.06%

洲America
40.33% 18.03%

洲Asia
11.77% 19.66%
內Taiwan
11.02% 16.04%
他 others
2.48% 1.21%
計Total
100.00% 100.00%

Unit: K NTD

2017.Jan~May 2016Y
營收Sales 511,728 1,903,100
營業成本COGS (359,928) (1,112,574)
毛利Gross Profit 151,800 790,526
毛利率 GP Ratio 29.7% 41.5%
營業費用Operating Expenses (56,844) (274,069)
營業利益Operating Income 94,956 516,457
營業外損益Non-Operating In/Ex (3,917) (10,758)
稅前淨利 Net Profit before Tax 91,039 505,699
所得稅Income Tax (88,744)
本期淨利Net Profit after Tax 416,955

產品組合-Products

Y2014 % Y2015 % Y2016 %
VA Series 21.89% HOCLQ 21.52% HOCLQ 34.94%
PGA 17.49% VA Series 18.21% PGA 12.73%
LPF.Na 8.74% PGA 17.14% VA Series 13.55%
S20/38 8.25% LPF.Na 7.48% Pent-2 / PEB.Na 6.70%
Pent-2 / PEB.Na 6.85% 5-HMT / 5-wing 4.61% S-MMAA / Dulo 5.32%
5-HMT / 5-wing 4.65% Pent-2 / PEB.Na 4.47% 5-HMT / 5-wing 5.21%
DBS 4.60% S20/38 4.01% LPF.Na 4.01%
S-MMAA / Dulo 2.64% S-MMAA / Dulo 3.81%
Total 75.11% Total 81.25% Total 82.46%

Product % 2017 1H Sales (NT\$)
S-MMAA / Dulo 16.4 100,508,859
VA series 14.43 88,449,219
LPF.Na 11.96 73,264,404
Pent-2 / PEB.Na 9.36 57,362,144
5-HMT / 5-wing 9.23 56,582,452
PGA 5.43 33,264,396
MQRT-115 5.06 30,999,600

Hydroxychloroquine sulfate

風濕性關節炎藥物 For rheumatoid arthritis treatment

Unit : K NT\$

產品介紹Product

VA series-

Unit : K NT\$

Valproic Acid, Divalproex Sodium, Sodium Valproate

Di-Va學名藥於2009推出 Di-Va generic came out in 2009

Pyrogallolaldehyde ( PGA) - Benserazide

Unit : K NT\$

治療帕金森氏症之中間體 Intermediate for Parkinson's Disease

產品介紹Product

Pent-2/Pentobarbital Sodium

Unit : K NT\$

鎮定安眠用中間體及原料藥 Intermediate and API for calmative

S-MMAA/Duloxetine

Unit : K NT\$

抗憂鬱症藥物 Antidepressant

2013年底Duloxetine專利到期 Duloxetine's patent expired in the end of 2013

5-HMT/Wing

Unit : K NT\$

愛滋病藥物中間體 For AIDS treatment Intermediates for Ritonavir and Lopinavir

Loxoprofen sodium Unit : K NT\$

抗發炎藥物 日本市場200-300公噸 Anti-inflammatory Japan market:200-300MT

GMP Status(GMP現況)

API CGMP CEP DMF MF DMF
Certified
(TFDA)
(EDQM) (USA) (Japan) (Canada)
Valproic Acid (*) (#) 2003 2004 2003 2008 2008
Allopurinol 2004 2003 2011
Sodium
Valproate
2004 2006
Divalproex
Sodium
(**)(#)
2005 2005 2010
Bisoprolol
Fumarate
2006
Pentobarbital
Sodium
2009 2
011
Propafenone
Hydrochloride
2010 2012 2010 2012 2012
Methylphenidate
HCl
2
011
2014
Duloxetine
Hydrochloride
2012 2014 2010/2011 2016
Thiopental 2012
Loxoprofen
Sodium
Hydrate
2012 2011
Articaine
Hydrochloride
2013 2014 2014
Hydroxychloroquine
Sulfate(#)
2014 2014 2014
Clindamycin
Palmitate
HCl
2011
Cyclophosphamide 2014 2012
Brinzolamide 2015 2015
Probucol 2015 2004 2015
Atomoxetine HCl 2016

(*)(**) FDA inspection: Nov. 2005 / April 2012, (*) EDQM inspection: Nov. 2010, (#) FDA inspection: Dec. 2014.

敬 請 指 教